CTMX (CytomX Therapeutics) Total Liabilities: $39.41 Mil (As of Mar. 2026)

What is CytomX Therapeutics Total Liabilities?

CytomX Therapeutics CTMX +3.66% 36 Total Liabilities is $39.41 Mil as of Mar. 2026. GuruFocus rates CTMX with a GF Score™ of 36/100 and a GF Value™ of $0.28 (Significantly Overvalued). The stock has 4 warning signs investors should review.

CytomX Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 was $39.41 Mil.

CytomX Therapeutics's quarterly Total Liabilities increased from Sep. 2025 ($50.87 Mil) to Dec. 2025 ($52.56 Mil) but then declined from Dec. 2025 ($52.56 Mil) to Mar. 2026 ($39.41 Mil).

CytomX Therapeutics's annual Total Liabilities declined from Dec. 2023 ($249.24 Mil) to Dec. 2024 ($120.99 Mil) and declined from Dec. 2024 ($120.99 Mil) to Dec. 2025 ($52.56 Mil).

CytomX Therapeutics Total Liabilities Related Terms

CytomX Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for CytomX Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CytomX Therapeutics Total Liabilities Chart

CytomX Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Total Liabilities

Get a 7-Day Free Trial

339.87

346.64

249.24

120.99

52.56

CytomX Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Total Liabilities	Get a 7-Day Free Trial															73.45	55.15	50.87	52.56	39.41

36GF Score

CytomX Therapeutics Inc CTMX

Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

CytomX Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

CytomX Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	46.615	+	(0	+	4.353
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	1.59	+	0	+	0)
	=	52.56

Total Liabilities	=	Total Assets (A: Dec. 2025 )	-	Total Equity (A: Dec. 2025 )
	=	151.566	-	99.008
	=	52.56

CytomX Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	34.023	+	(0	+	4.412
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0.979	+	0	+	0)
	=	39.41

Total Liabilities	=	Total Assets (Q: Mar. 2026 )	-	Total Equity (Q: Mar. 2026 )
	=	359.358	-	319.944
	=	39.41

Frequently Asked Questions Learn more about Total Liabilities →

What does a Total Liabilities of $39.41 Mil mean?

CytomX Therapeutics (CTMX) has a Total Liabilities of $39.41 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for CytomX Therapeutics and its competitors.

Is CytomX Therapeutics' Total Liabilities too high?

CytomX Therapeutics' current Total Liabilities is $39.41 Mil. Overall, CytomX Therapeutics has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does CytomX Therapeutics' Total Liabilities compare to SMNR and AURA?

CytomX Therapeutics' Total Liabilities of $39.41 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Total Liabilities for a Biotechnology company?

A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Total Liabilities mean?

A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for CytomX Therapeutics and its competitors. CytomX Therapeutics's current Total Liabilities is $39.41 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is CytomX Therapeutics stock overvalued right now?

Based on GuruFocus' analysis, CytomX Therapeutics (CTMX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.28, compared to a current price of $3.38 — trading 1107.1% above its estimated fair value. The current Total Liabilities is $39.41 Mil. CytomX Therapeutics' overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Total Liabilities calculated?

Total Liabilities is calculated from a company's financial statements. For CytomX Therapeutics (CTMX), the current Total Liabilities is $39.41 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CytomX Therapeutics (CTMX) Overvalued in 2026?

Based on GuruFocus' analysis, CytomX Therapeutics stock appears to be overvalued. The current stock price of $3.38 is trading 1107.1% above its estimated GF Value™ of $0.28. GuruFocus considers CytomX Therapeutics to be Significantly Overvalued.

Key valuation signals for CTMX:

Total Liabilities: $39.41 Mil
GF Value™: $0.28 vs. price of $3.38 (1107.1% above fair value)
GF Score™: 36/100 with 4 warning signs

No single metric tells the full story. See the CTMX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CytomX Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies SMNR AURA OMER PHAT GERN LBRX ODTX VOR RLMD ALLO VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges 6C1:Germany

Address 151 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080

Website https://www.cytomx.com

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

36GF Score

Get the complete analysis for CTMX

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.38

Price

$0.28

GF Value

View CTMX Analysis

See Total Liabilities data for all stocks →